Replies to post #159 on Trillium Therapeutics Inc (TRIL)

[RockRat]

>>I am speculating that we will see Phase I data at Asco...will have to watch volume for clues

They started dosing 2/3 so they should see results for first patients by now...will be interesting for the next 30 days to pick up clues.<<

I'll take the other side of that speculation:

2016 ASCO key dates

It's fairly unusual for interim Phase 1 data to be presented, anyway. Though maybe less so the last few years. Still, I don't see how they make the deadline. Even a late breaker seems highly unlikely to me. I think ASH is more likely. It's possible they could present something before then at a relatively minor conference, but I wouldn't bank on that, either.

Edit: Abstract titles come out 4/20.

Regards, RockRat

[RockRat]

Well, I guess I lost our little side bet: Trillium is in fact presenting early data at ASCO:

<<Abstract TPS7585
A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory hematologic malignancies.

Poster Board: #134b
Stephen Maxted Ansell, MD - Presenter
Division of Hematology, Mayo Clinic<<

This is June 6th in the morning session.

Times are a-changing.

Regards, RockRat